Ohio State Navbar

Directory

Don Benson Jr., MD, PhD


Staff photo

320 W 10th Ave
Columbus, OH 43210

Phone: (614) 366-3802

Email: benson.236@osu.edu

 

Current OSU Appointments

Associate Professor-Clinical, Hematology

Physician, FGP-Hematology

 

Advising Narrative

Ms. Bakan has co-authored three peer-reviewed, published manuscripts under my mentorship to date and has presented first author, peer reviewed abstracts under my mentorship at local and regional cancer research meetings. Ms. Collins is a student in the undergraduate Biomedical Sciences Program at The Ohio State University. Under my mentorship, she was awarded a competitive grant in the Internal Medicine Summer Internship Project. Following that experience, she formally joined our laboratory and she is currently one of only very few, two-time recipients of the Pelotonia Undergraduate Fellowship to fund her work in my laboratory. This has led to a number of first-author, peer-reviewed published abstracts and local, regional, and national presentations of her research under my mentorship. Under my mentorship, Ms. Collins has received awards for her work including: Third Place, Health Professions: Laboratory/Cellular Division, Denman Undergraduate Annual Research Forum, 2011, The Ohio State University, and Second Place, Innate Immunity Division, The Ohio State University Comprehensive Cancer Center Annual Scientific Meeting, 2011. She is the first author of a manuscript in preparation for submission to a high-impact journal summarizing her work. Mr. Alghothani is an undergraduate in Biology at The Ohio State University who originally joined my laboratory research group in the summer between his high school and college training. Yousef has co-authored a number of peer reviewed, published abstracts with me. Mr. Alghothani is the second undergraduate under my mentorship to be awarded a Pelotonia Undergraduate Fellowship (2011) to fund his research in my laboratory for his senior year of undergraduate training.

Certifications

2003 - present Ohio Medical License: State Medical Board of Ohio
2006 - present Diplomate: American Board of Internal Medicine
2001 Comprehensive Introduction to Clinical Investigation: University of Virginia
2001 - 2004 Virginia Board of Health Professions: Virginia Board of Health Professions
2002 - 2012 Diplomate: American Board of Internal Medicine
 

Chapters in Books

Benson Jr., Don. "Alzheimer's disease." In Forgetting and Amnesia. -. North Chelmsford: Erudition Books, January 2002.

Benson Jr., Don. "Korsakoff Syndrome." In Forgetting and Amensia. -. Noth Chelmsford: Erudition Books, January 2002.

Benson DM Jr and Caligiuri MA. "Natural Killer Cell Immunity." In Hoffman’s Hematology, 5th edition. 5th ed. -. Philadelphia, PA: Elsevier, January 2008.

 

Clinical Services

12/01/2011 HNP Inpatient Service (James Cancer Hospital)
04/01/2012 Hematology I Inpatient Service (James Cancer Hospital)
06/01/2012 BMT Inpatient Service, James (James Cancer Hospital)

Degrees

1992 B.A., Wheeling Jesuit University

1994 M.A., Kent State University

1999 M.D., Northeastern Ohio Universities College of Medicine

1999 Ph.D., Kent State University

 

Editorial Activities

2006 - present Clinical Cancer Research
2006 - present Blood
2008 - present Cytotherapy
2008 - present Bone Marrow Transplantation
2011 - present Cancer Research
2012 - present First Consult
2012 - present Leukemia and Lymphoma
2012 - present International Journal of Hematologic Oncology
 

Honors

1988 - 1992 Loyola Scholarship.
1989 - present Gloriam Award for Leadership and Academic Excellence. Wheeling Jesuit College.
1989 - present Collegian of the Year Award. Wheeling Jesuit College.
1990 - present Gloriam Award for Leadership and Academic Excellence. Wheeling Jesuit College.
1991 - present Sportsman Award, Men's Soccer. Wheeling Jesuit College.
1991 - present National Honor Society for Psychology - 1990-91, chapter vice-president, 1991-92, chapter president. Psi Chi.
1991 - present National Honor Society for Philosophy. Phi Sigma Tau.
1991 - present All-Conference Scholar Athlete, Men's Soccer. WVIAC.
1991 - present Academic All-American Team, Men's Soccer. NCAA/NAIA.
1991 - 1992 Alpha Sigma Nu, National Honor Society of Jusuit Colleges and Universities. Chapter vice-president.
1992 - present Stephen J. Laut SJ Honors Graduate. Wheeling Jesuit College.
1998 Alpha Omega Alpha, National Honor Society for Medicine.
1999 - present Matthew Allen Lewis Memorial Award for the Mastery of the Art and Science of Medicine. Northeastern Ohio Universities College of Medicine.
1999 - present William H Falor Award for Research. Northeastern Ohio Universities College of Medicine.
1999 - present Hoecht, Marion and Roussell Award for Outstanding Achievement. Northeastern Ohio Universities College of Medicine.
2000 - present University of Virginia School of Medicine Housestaff Award for Excellence in Teaching,. University of Virginia.
2001 - present University of Virginia School of Medicine Housestaff Award for Excellence in Teaching. University of Virginia.
2001 - present University of Virginia All-University Award for Excellence in Teaching. Graduate School of Arts & Sciences.
2002 - present Graduate of the Last Decade (GOLD) Award. Wheeling Jesuit University.
2002 - present University of Virginia School of Medicine Housestaff Award for Excellence in Teaching. University of Virginia.
2006 - present Merit Award. American Society of Clinical Oncology.
2008 - present Team in Training "Honored Doctor" Award. The Leukemia and Lymphoma Society.
2009 - present Chairman's Citation for Outstanding Service to the Community. The Leukemia and Lymphoma Society.
2009 - present "Forty under 40" Award. Business First - Columbus OH.
2009 - present Med I/II Integrated Pathway Faculty Recognition Award. Med I/II Integrated Pathway.
2009 - present Outstanding Teaching Award. Med I/II Integrated Pathway.
2009 DiscoverMMORE Award. Multiple Myeloma Opportunities for Research and Education.
2010 - present Med I/II Integrated Pathway Faculty Recognition Award. Med I/II Integrated Pathway.
2011 - present Student Mentor of the Year. Department of Internal Medicine.
2011 - present Landacre Honor Society Mentor of the Year Award. Landacre Honor Society, The Ohio State University College of Medicine.
2011 - present Alpha Omega Alpha Gamma Chapter Faculty Recognition Award. Alpha Omega Alpha Medical Honor Society.
2012 Professor of the Year. The Ohio State University College of Medicine.
2013 - present Excellence in Teaching Award. Department of Internal Medicine, The Ohio State University College of Medicine.
2013 - present Courage to Teach Award. Council for Humanism, Medicine and the Arts Program, The Ohio State University College of Medicine.
2014 - present Longitudinal Practice Preceptor of the Year. College of Medicine, The Ohio State University.
2014 - present Inductee. Gold Humanism Honor Society.
 

Journal Articles

Flint, RW, Metzger, MM, Benson, DM, & Riccio DC. "Stress-induced memory enhancement for inhibitory fear conditioning in rats." Psychobiology. no. 25. (January 1997.): 89-94.

Fountain, SB, Rowan, JD, Benson, DM. "Rule learning in rats: serial tracking of interleaved patterns." Animal Cognition. no. 2. (January 1999.): 41-54.

Rickman, T, Daugherty, T, Benson DM, & Okusa MD. "Hypokalemia, metabolic alkalosis, and hypertension: Cushing's syndrome in a patient with metastatic prostate adenocarcinoma." American Journal of Kidney Diseases. Vol. 4, no. 36. (January 2001.): 838-846.

Bednarz-Volk, A, Benson, DM Jr, Sydnor, ERM, and Scheld, M. "Invasive Aspergillus niger infection with pulmonary oxalate crystals in an immunocompetent host: case report and review of the literature." Southern Medical Journal. no. 96. (January 2003.): s59-.

Benson DM Jr, Odonnell L, Krugh D, Grady T, Blum W, Williams J, Kennedy M, Marcucci G. "Successful management of sudden, massive immune hemolysis following ABO-incompatible allogeneic PBSCT despite methotrexate GvHD prophylaxis." Bone Marrow Transplant. Vol. 36, (January 2005.): 1111-1112.

Yu J, Wei M, Becknell B, Trotta R, Liu S, Boyd Z, Jaung MS, Blaser BW, Sun J, Benson DM Jr, Mao H, Yokohama A, Bhatt D, Shen L, Davuluri R, Weinstein M, Marcucci G, Caligiuri MA.. "Pro- and anti-inflammatory cytokine signaling: reciprocal antagonism regulates interferon-gamma production by human natural killer cells." Immunity. Vol. 24, (May 2006.): 575-590.

Cataland, Spero R.; Kraut, Eric H.; Benson, Don; Ferketich, Amy K.; Horne, April; Jin, Ming; George, James N.; Wu, Haifeng M.. "Improved clinical outcome and Adamts13 activity after concurrent cyclosporine and plasma exchange in TTP.." Blood. Vol. 108, no. 11, Part 1. (January 2006.): 314A-.

Khan,Khuda,D; Emmanouilides,Christos; Benson,Don,M; Hurst,Deborah; Garcia,Pablo; Michelson,Glenn; Milan,Sandra; Ferketich,Amy,K; Piro,Lawrence; Leonard,John,P; Porcu,Pierluigi; Eisenbeis,Charles,F; Banks,Amy,L; Chen,Lei; Byrd,John,C; Caligiuri,Michael,A. "A phase 2 study of rituximab in combination with recombinant interleukin-2 for rituximab-refractory indolent non-Hodgkin's lymphoma." Clinical Cancer Research. Vol. 12, no. 23. (December 2006.): 7046-7053.

Shah MH, Freud AG, Benson DM Jr, Ferkitich AK, Dezube BJ, Bernstein ZP, Caligiuri MA. "A phase I study of ultra low dose interleukin-2 and stem cell factor in patients with HIV infection or HIV and cancer.." Clinical Cancer Research. Vol. 12, no. 13. (July 2006.): 3993-3996.

Fountain, Stephen B.; Benson, Don M., Jr.. "Chunking, rule learning, and multiple item memory in rat interleaved serial pattern learning." Learning and Motivation. Vol. 37, no. 2. (January 2006.): 95-112.

Benson, Don M, Jr.; Briesewitz, Roger; Becknell, M. Brian; Trotta, Rossana; Caligiuri, Michael A.. "Mechanism of synergistic proliferation in response to Il-2/15 and c-kit ligand involves both structural and functional cooperation: Insights into lymphohematopoietic stem cell expansion.." Proceedings of the American Association for Cancer Research Annual Meeting. Vol. 47, (March 2006.): 1133-.

Hamadani M, Benson DM Jr, Copelan EA. "Thalidomide-induced fulminant hepatic failure." Mayo Clinic Proceedings. Vol. 82, no. 5. (January 2007.): 638-.

Hamadani M, Martin LK, Benson DM Jr , Copelan EA, Devine SM, Hofmeister CC. "Central nervous system post-transplant lymphoproliferative disorder despite negative serum and spinal fluid Epstein-Barr virus DNA PCR.." Bone Marrow Transplantation. Vol. 39, no. 4. (January 2007.): 249-251.

Benson DM Jr, Elder PJ, Lin TS, Blum W, Penza S, Avalos B, Copelan E, Farag SS. "A comparison of high-dose melphalan versus busulfan, cyclophosphamide, and etoposide as preparative regimens for autologous stem cell transplantation in patients with multiple myeloma." Leukemia Research. Vol. 31, no. 8. (January 2007.): 1069-1075.

Benson DM Jr, Smith MK. "Effectiveness of lenalidomide (Revlimid) for the treatment of plasma cell leukemia.." Leukemia & Lymphoma. Vol. 48, no. 7. (January 2007.): 1423-1425.

Becknell B, Hughes TL, Freud AG, Blaser BW, Yu J, Trotta R, Mao HC, Caligiuri de Jesús ML, Alghothani M, Benson DM Jr, Lehman A, Jarjoura D, Perrotti D, Bates MD, Caligiuri MA. "The Hlx homeobox transcription factor negatively regulates interferon-gamma production in monokine-activated natural killer cells." Blood. Vol. 109, (January 2007.): 2481-2487.

Arce-Lara C, Shah MH, Jimenez RE, Patel VR, Benson DM Jr, Clinton SK, Monk JP. "Gastrointestinal stromal tumors involving the prostate: Presentation, course, and therapeutic approach." Urology. Vol. 69, no. 6. (January 2007.): e5-7.

Vrindavanam, N Hamadani, M Steele, B; Awan F, Suster S, Benson DM Jr. "Dramatic response to single-agent rituximab in a patient with intravascular lymphoma." American Journal of Hematology. Vol. 82, no. 12. (January 2007.): 1120-1121.

Benson DM Jr. "Focus on Fellows and Junior Faculty: Keys to obtaining research funding." ASCO News and Forum. (July 2007.): 54-59.

Benson DM Jr, Smith MK, Krugh, D, Devine, SM. "Successful therapy of chronic graft-versus-host disease manifesting as pure red cell aplasia with single-agent rituximab.." Bone Marrow Transplantation. Vol. 41, no. 6. (January 2008.): 595-596.

Kondadasula SV, Varker KA, Lesinski GB, Benson DM Jr, Lehman A, Olenki T, Monk P, Kendra K, Carson WE III. "Activation of extracellular signaling regulated kinase in nautral killer cells and monocytes following IL-2 stimulation in vitro and in patients undergoing IL-2 immunotherapy: Analysis via dual parameter flow cytometric assay." Cancer Immunolology and Immunotherapy. Vol. 57, no. 8. (January 2008.): 1137-1149.

Yang EV, Donovan EL, Benson DM Jr, Glaser R. "VEGF is differentially regulated in multiple-myeloma derived cell lines by norepinephrine." Brain, Behavior, and Immunity. Vol. 22, no. 3. (January 2008.): 318-323.

Hofmeister CC, Jansak B, Denlinger N, Kraut EH, Benson DM Jr, Farag SS. "Phase II clinical trial of arsenic trioxide with liposomal doxorubicin, vincristine, and dexamethasone in newly diagnosed multiple myeloma.." Leukemia Research. Vol. 32, no. 8. (January 2008.): 1295-1298.

Hamadani M, Hade E, Benson DM Jr, Hofmeister CC. "The effect of statin use at the time of autologous transplant on response and survival in multiple myeloma. Biol Blood Marrow Transplant." Biology of Blood and Marrow Transplantion. Vol. 14, (January 2008.): 351-352.

Hamadani M, Benson DM Jr, Blum W, Garzon R, Devine SM. "Pulmonary Nocardia and Aspergillus co-infection in a patient with chronic graft-versus-host disease.." Transplant Infectious Disease. Vol. 10, no. 1. (January 2008.): 24-26.

Yang, Benson DM Jr, Glaser R. "Catecholamines can mediate stress-related effects on tumor progression." Vol. 3, (January 2008.): 699-703.

Hamadani M*, Benson DM Jr ,* Lin TS, Porcu P, Blum KA, Devine SM. "High-dose therapy and autologous stem cell transplantation for follicular lymphoma undergoing transformation to diffuse large B-cell lymphoma." European Journal of Haematolology. Vol. 81, no. 6. (January 2008.): 425-431.

Hamadani,Mehdi; Awan,Farrukh,T; Elder,Patrick; Lin,Thomas,S; Porcu,Pierluigi; Benson,Don,M; Blum,Kristie,A; Devine,Steven,M. "Feasibility of allogeneic hematopoietic stem cell transplantation for follicular lymphoma undergoing transformation to diffuse large B-cell lymphoma." Leukemia & Lymphoma. Vol. 49, no. 10. (January 2008.): 1893-1898.

Yu J, Wei M, Mao C, Hughes T, Trotta R, Park IK, Mitsui T, Hwang C, Liu S, Jarjoura D, Benson DM Jr,Caligiuri MA. "CD94 defines distinct NK1.1 mouse and CD56dim human natural killer cell subsets." Journal of Immunology. Vol. 183, (January 2009.): 4968-4974.

Bill M, Bakan C, Benson DM Jr, Fuchs J, Young G, Lesinksi GB. "Curcumin induces pro-apoptotic effects on human melanoma cells and modulates the cellular response to immunotherapeutic cytokines.." Molecular Cancer Therapeutics. Vol. 8, (January 2009.): 2726-2735.

Hamadani,Mehdi; Blum,William; Phillips,Gary; Elder,Patrick; Andritsos,Leslie; Hofmeister,Craig; O'Donnell,Lynn; Klisovic,Rebecca; Penza,Sam; Garzon,Ramiro; Krugh,David; Lin,Thomas; Bechtel,Thomas; Benson,Don,M; Byrd,John,C; Marcucci,Guido; Devine,Steven,M. "Improved Nonrelapse Mortality and Infection Rate with Lower Dose of Antithymocyte Globulin in Patients Undergoing Reduced-Intensity Conditioning Allogeneic Transplantation for Hematologic Malignancies." BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION. Vol. 15, no. 11. (November 2009.): 1422-1430.

Benson DM Jr, Yu J, Becknell B, Wei M, Freud A, Ferketich AK, Trotta R, Perrotti D, Briesewitz R, Caligiuri MA. "Stem cell factor and interleukin-2/15 combine to enhance MAPK-mediated proliferation of human natural killer cells." Blood. Vol. 113, no. 12. (January 2009.): 2706-2714.

Hamadani M, Benson DM Jr, Hofmeister CC, Elder P, Blum W, Porcu P, Garzon R, Blum KA, Lin TS, Marcucci G, Devine SM. "Allogeneic stem cell transplantation for patients with relapsed chemorefractory aggressive non-Hodgkin lymphomas." Biology of Blood and Marrow Transplantation. Vol. 15, (January 2009.): 547-553.

Yu,Jianhua; Wei,Min; Mao,Hsiaoyin; Zhang,Jianying; Hughes,Tiffany; Mitsui,Takeki; Park,Il-Kyoo; Hwang,Christine; Liu,Shujun; Marcucci,Guido; Trotta,Rossana; Benson,Don,M; Caligiuri,Michael,A. "CD94 Defines Phenotypically and Functionally Distinct Mouse NK Cell Subsets." JOURNAL OF IMMUNOLOGY. Vol. 183, no. 8. (October 2009.): 4968-4974.

Hamadani M, Blum W, Phillips G, Elder P, Andritsos L, Hofmeister CC, O’Donnell L, Klisovic R, Penza S, Garzon R, Krugh D, Lin TL, Benson DM Jr, Marcucci G, Devine SM.. "Modest dose reduction of ATG improves non-relapse mortality and infection complications following reduced intensity conditioning allogeneic transplantation without compromising GVHD control." Biolology of Blood and Marrow Transplantation. Vol. 15, (January 2009.): 1422-1430.

Romagne F, Andre P, Spee P, Zahn S, Anfossi N, Gauthier L, Capanni M, Ruggeri L, Benson DM Jr, Blaser BW, Dellar Chiesa M, Moretta A, Vivier E, Caligiuri MA, Velardi A, Wagtmann N. "Preclinical characterization of 1-7F9, a novel human anti-KIR therapeutic antibody that augments NK-mediated killing of tumor cells." Blood. Vol. 114, (January 2009.): 2667-2677.

Murphy CL, Wang S, Kestler D, Larsen C, Benson DM Jr , Weiss DT, Solomon A. "Leukocyte chemotactic factor 2 (LECT-2)-associated renal amyloidosis: a case series." American Journal of Kidney Diseases. Vol. 56, no. 6. (December 2010.): 1100-1107.

Lin L, Deangelis S, Foust E, Fuchs J, Li C, Li, P-K, Schwartz EB, Lesinski GB, Benson DM Jr , Lu J, Hoyt D, Lin J.. "A novel small molecule inhibits STAT3 phosphorylation and DNA binding activity and exhibits potent growth suppressive activity in human cancer cells.." Molecular Cancer. Vol. 9, (January 2010.): 217-227.

Benson DM Jr, Bakan CE, Mishra A, Biaocchi R, Chandler J, Hofmeister CC, Efebera Y, Smith MK, Greenfield C, Lozanski G, Byrd JC, Rotem-Yehudar R, Caligiuri MA. "The PD-1 / PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a novel therapeutic target for CT-011, a monoclonal PD-1 antibody." Blood. Vol. 116, no. 13. (January 2010.): 2286-2294.

Pichiorri F, Suh S-S, Rocci A, De Luca L, Taccioli C, Ramasamy S, Wenchao Z, Lin H-J, Benson DM Jr , Hofmeister C, Hansjuerg A, Garofalo M, Di Leva G, Perroti D, Kuehl M, Palumbo A, Aqeilan RI,. "Down-regulation of p53-inducible microRNAs 192, 194, and 215 impairs the p53/MDM2 auto-regulatory loop in multiple myeloma development." Cancer Cell. Vol. 18, no. 4. (January 2010.): 367-381.

Murphy C, Wang S, Kestler D, Larsen C, Benson DM Jr , Weiss D, Solomon A. "Leukocyte chemotactic factor 2 (LECT-2)-associated renal amyloidosis." Amyloid - International Journal of Experimental and Clinical Investigation. Vol. 18, no. Suppl 1. (June 2010.): 218-220.

Blum,Kristie,A; Liu,Zhongfa; Lucas,David,M; Chen,Ping; Xie,Zhiliang; Baiocchi,Robert; Benson,Donald,M; Devine,Steven,M; Jones,Jeffrey; Andritsos,Leslie; Flynn,Joseph; Plass,Christoph; Marcucci,Guido; Chan,Kenneth,K; Grever,Michael,R; Byrd,John,C. "Phase I trial of low dose decitabine targeting DNA hypermethylation in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: dose-limiting myelosuppression without evidence of DNA hypomethylation." BRITISH JOURNAL OF HAEMATOLOGY. Vol. 150, no. 2. (July 2010.): 189-195.

Hofmeister CC, Jin M, Cataland SR, Benson DM Jr, Wu HM. "TTP disease course is independent of myeloma treatment and response.." American Journal of Hematology. Vol. 85, (January 2010.): 304-306.

Benson DM Jr, Panzner K, Hamadani M, Hofmeister CC, Bakan C, Smith MK, Elder P, Krugh D, O’Donnell L, Devine SM. "Effects of induction with novel agents versus conventional chemotherapy on mobilization and autologous stem cell transplant outcomes in multiple myeloma." Leukemia & Lymphoma. Vol. 51, no. 2. (January 2010.): 243-251.

Awan FT, Lapalombella R, Trotta R, Butchar JP, Benson DM Jr, Yu B, Cheney C, Mo X, Lehman A, Jones J, Flynn J, Jarjoura D, Desjarlais JR, Tridandapani S, Caligiuri MA, Muthusamy R, Byrd JC.. "CD19 targeting of lymphoid malignancies by a novel Fc-domain engineered monoclonal antibody." Blood. Vol. 115, (January 2010.): 1422-1430.

Blum KA, Liu Z, Lucas DM, Baiocchi R, Benson DM Jr, Devine SM, Jones J, Andritsos L, Flynn J, Chen P, Xie Z, Marcucci G, Chan KK, Grever MR, Byrd JC.. "Phase 1 trial of low dose decitabine targeting DNA hypermethylation in patients with chronic lymphocytic leukemia and non-Hodgkin lymphoma: dose limiting myelosuppression without evidence of DNA hypomethylation." British Journal of Heamatology. Vol. 150, no. 2. (January 2010.): 189-195.

Bill MA, Fuchs JR, Li C, Yui, Bakan C, Benson DM Jr, Schwartz EB, Abdelhamid D, Lin J, Hoyt DG, Fossey SL, Young GS, Carson III WE, Li PK, Lesinski GB. "The small molecule curcumin analog FLLL32 induces apoptosis in melanoma cells via STAT3 inhibition and retains the cellular response to cytokines with anti-tumor activity.." Molecular Cancer. Vol. 9, no. 25. (January 2010.): 165-177.

Hofmeister CC, Yang X, Chen P, Rozewski DM, Johnson A, Lee S, Liu Z, Hade E, Schaaf L, Benson DM Jr, Chan KK, Chen C-S, Farag SS, Grever MR, Byrd JC, Phelps MA.. "Phase I trial of lenalidomide and CCI-779 in patients with relapsed multiple myeloma: evidence for lenalidomide-CCI-779 interaction via P-glycoprotein." Journal of Clinical Oncology. Vol. 29, no. 25. (January 2011.): 3427-3434.

Hamadani M, Craig M, Phillips GS, Abraham J, Tse W, Cumpston A, Gibson L, Remick SC, Bunner P, Leadmon S, Elder P, Hofmeister C, Penza S, Efebera Y, Andritsos L, Garzon R, Benson DM Jr, Blum W, Devine SM. "Higher busulfan dose intensity does not improve outcomes of patients undergoing allogeneic haematopoietic stem cell transplantation following fludarabine, busulfan-based reduced toxicity conditioning." Hematological Oncology. Vol. 29, no. 4. (February 2011.): 202-210.

Lin L, Benson DM Jr, Deangelis S, Bakan CE, Li PK, Li C, Lin J. "A small molecule LLL12 inhibits constitutive STAT3 phosphorylation and IL-6 induced STAT3 signaling and exhibits potent growth suppressive activity in human muiltiple myleoma cells." International Journal of Cancer. Vol. epub ahead of print, no. April 25, 2011. (April 2011.): 1459-1469.

Vogt SM, Crawford B, Roddy J, Phillips G, Elder P, Hofmeister C, Efebera Y, Benson DM Jr. "Serum free light chains in myeloma patients with an intact M-protein by immunofixation: potential roles for response assessment and prognosis during induction therapy with novel agents." Hematol Oncol. Vol. epub ahead of print, no. October 26, 2011. (June 2011.): 156-162.

Yu J, Mitsui T, Wei M, Mao H, Shah MV, Yokohama A, Zhang J, Benson DM Jr , Loughran TP, Caligiuri MA. "NKp46 identifies an NKT cell subset likely susceptible to malignant transformation in mouse and man.." Journal of Clinical Investigation. Vol. 121, no. 4. (January 2011.): 1456-1470.

Benson DM, Jr , Bakan CE, Zhang S, Collins SM, Liang J, Srivastava S, Hofmeister CC, Efebera Y, Andre P, Romagne F, Blery M, Bonnafous C, Zhang J, Clever D, Caligiuri MA, Farag SS. "IPH2101, a novel anti-inhibitory KIR antibody, and lenalidomide combine to enhance the natural killer cell versus multiple myeloma effect." Blood. Vol. 118, no. 24. (January 2011.): 6387-6391.

Benson DM Jr and Byrd JC. "Understanding the Pathway: CS-1 mediated monoclonal antibody therapy for myeloma." Journal of Clinical Oncology. (January 2012.): -.

Godfrey,James; Benson,Don,M. "The role of natural killer cells in immunity against multiple myeloma." LEUKEMIA & LYMPHOMA. Vol. 53, no. 9. (September 2012.): 1666-1676.

Vey N, Bourhis JH, Boisse N l, Bordessoule D, Prebet T, Charbonnier A, Etienne A, Andre P, Romagne F, Benson DM, Dombret H, Olive D. "A phase 1 trial of the anti-inhibitory KIR mAb IPH2101 for AML in complete remission." Blood. Vol. 120, (October 2012.): 4317-4323.

Benson D M Jr, Hofmeister CC., Padmanabhan S, Suvannasankha A, Jagannath S, Abonour R, Bakan C, Andre P, Efebera Y, Tiollier J, Caligiuri M A, Farag SS.. "A phase 1 trial of the anti-KIR antibody IPH2101 in patients with relapsed/refractory multiple myeloma." Blood.. Vol. 120, (October 2012.): 4324-4333.

Benson,D,M. "ANTI-KIR STRATEGY IN CANCER TREATMENT." DRUGS OF THE FUTURE. Vol. 38, no. 2. (February 2013.): 99-105.

Burkart,Jarred; Benson,Don,Michael. "When first line therapy for AA-amyloidosis secondary to rheumatoid arthritis fails: A correspondence." JOINT BONE SPINE. Vol. 80, no. 2. (March 2013.): 229-230.

Roth,Rachel,M; Benson,Don; Hebert,Lee,A; Bissell,Michael,G; Satoskar,Anjali,A; Nadasdy,Tibor; Brodsky,Sergey,V. "Progressive Renal Light Chain Amyloidosis With the Absence of Detectable Free Monoclonal Light Chains After an Autologous Hematopoietic Stem Cell Transplant for Amyloid Light Chain Amyloidosis." ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE. Vol. 137, no. 9. (September 2013.): 1304-1308.

Collins,Shauna,M; Bakan,Courtney,E; Swartzel,Gina,D; Hofmeister,Craig,C; Efebera,Yvonne,A; Kwon,Hakju; Starling,Gary,C; Ciarlariello,David; Bhaskar,Shakthi; Briercheck,Edward,L; Hughes,Tiffany; Yu,Jianhua; Rice,Audie; Benson,Don,M. "Elotuzumab directly enhances NK cell cytotoxicity against myeloma via CS1 ligation: evidence for augmented NK cell function complementing ADCC." CANCER IMMUNOLOGY IMMUNOTHERAPY. Vol. 62, no. 12. (December 2013.): 1841-1849.

Dunavin,Neil,C; Wei,Lai; Elder,Patrick; Phillips,Gary,S; Benson,Don,M; Hofmeister,Craig,C; Penza,Sam; Eld,Carli,Greenfi; Rose,Karen,S; Rieser,Gisele; Merritt,Lisa; Ketcham,Jill; Heerema,Nyla; Byrd,John,C; Devine,Steven,M; Efebera,Yvonne,A. "Early versus delayed autologous stem cell transplant in patients receiving novel therapies for multiple myeloma." LEUKEMIA & LYMPHOMA. Vol. 54, no. 8. (August 2013.): 1658-1664.

Cohen,J,B; Hall,N,C; Ruppert,A,S; Jones,J,A; Porcu,P; Baiocchi,R; Christian,B,A; Penza,S; Benson,D,M; Flynn,J; Andritsos,L,A; Devine,S,M; Blum,K,A. "Association of pre-transplantation positron emission tomography/computed tomography and outcome in mantle cell lymphoma." BONE MARROW TRANSPLANTATION. Vol. 48, no. 9. (September 2013.): 1212-1217.

He,Shun; Chu,Jianhong; Wu,Lai-Chu; Mao,Hsiaoyin; Peng,Yong; Alvarez-Breckenridge,Christopher,A; Hughes,Tiffany; Wei,Min; Zhang,Jianying; Yuan,Shunzong; Sandhu,Sumeet; Vasu,Sumithira; Benson,Don,M; Hofmeister,Craig,C; He,Xiaoming; Ghoshal,Kalpana; Devine,Steven,M; Caligiuri,Michael,A; Yu,Jianhua. "MicroRNAs activate natural killer cells through Toll-like receptor signaling." BLOOD. Vol. 121, no. 23. (June 2013.): 4663-4671.

Yasmeen,R; Meyers,J,M; Alvarez,C,E; Thomas,J,L; Bonnegarde-Bernard,A; Alder,H; Papenfuss,T,L; Benson,D,M; Boyaka,P,N; Ziouzenkova,O. "Aldehyde dehydrogenase-1a1 induces oncogene suppressor genes in B cell populations." BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH. Vol. 1833, no. 12. (December 2013.): 3218-3227.

Harshman,Sean,W; Canella,Alessandro; Ciarlariello,Paul,D; Rocci,Alberto; Agarwal,Kitty; Smith,Emily,M; Talabere,Tiffany; Efebera,Yvonne,A; Hofmeister,Craig,C; Benson,Don,M; Paulaitis,Michael,E; Freitas,Michael,A; Pichiorri,Flavia. "Characterization of multiple myeloma vesicles by label-free relative quantitation." PROTEOMICS. Vol. 13, no. 20. (October 2013.): 3013-3029.

Jones,Jeffrey,A; Rupert,Amy,S; Poi,Ming; Phelps,Mitch,A; Andritsos,Leslie; Baiocchi,Robert; Benson,Don,M; Blum,Kristie,A; Christian,Beth; Flynn,Joseph; Penza,Sam; Porcu,Pierluigi; Grever,Michael,R; Byrd,John,C. "Flavopiridol can be safely administered using a pharmacologically derived schedule and demonstrates activity in relapsed and refractory non-Hodgkin's lymphoma." AMERICAN JOURNAL OF HEMATOLOGY. Vol. 89, no. 1. (January 2014.): 19-24.

Hofmeister,Craig,C; Poi,Ming; Bowers,Mindy,A; Zhao,Weiqiang; Phelps,Mitch,A; Benson,Don,M; Kraut,Eric,H; Farag,Sherif; Efebera,Yvonne,A; Sexton,Jennifer; Lin,Thomas,S; Grever,Michael; Byrd,John,C. "A phase I trial of flavopiridol in relapsed multiple myeloma." CANCER CHEMOTHERAPY AND PHARMACOLOGY. Vol. 73, no. 2. (February 2014.): 249-257.

Burkhart J & Benson DM Jr. "When first line therapy for AA-amyloidosis secondary to rheumatoid arthritis fails: a correspondence." Joint Bone Spine. -.

Roth RM, Hebert LA, Bissell MG, Satoskar AA, Nadasdy T, Benson DM Jr, Brodsky SV. "Progressive renal light chain amyloidosis with absence of detectable free monoclonal light chains afer autologous hepatopoietic stem cell transplant for AL amyloidosis.." Arch Path Lab Med. -.

Benson DM Jr.. "Can NKT cells extinguish “smoldering” myeloma.." Blood. -.

Rajappannair L, Lam E, Benson DM, Racke F, Devine SM, Zhao W.. "Collision anaplastic large cell lymphoma (T-cell/histiocyte-rich) and diffuse large B cell lymphoma: A pathologic and clinical evaluation." J Cancer Ther. -.

Jakubowiak AJ, Benson DM Jr , Bensinger W, Siegel DSD, Zimmerman TM, Mohrbacher A, Richardson PG, Afar DEH, Singhal AK, Anderson KC. "A phase 1 trial of anti-CS1 monoclonal antibody elotuzumab in combination with bortezomib in the treatment of relapsed/refractory multiple myeloma." Journal of Clinical Oncology. -.

 

Reference Works

January 2000 Benson, DM Jr.."Determining the cognitive mechanisms involved in rat interleaved serial pattern learning" . : 4937
January 2004 Benson, DM Jr, Elder, PJ, Lin, TS, Blum, W, Penza, S, Avalos, B, Byrd, JC, Copelan, E, and Farag, SS."Single institution experience with two high-dose chemotherapy conditioning regimens prior to autologous stem cell transplant for multiple myeloma" . : 104
January 2006 Benson DM Jr, Shah MS, Freud AG, Ferketich AK, Dezube BJ, Bernstein ZP, Caligiuri MA."A phase I study of ultra low dose interleukin-2 and stem cell factor in patients with cancer and or HIV infection." . : 2504
January 2006 Benson DM Jr, Briesewitz R, Becknell MB, Trotta R, Caligiuri MA."Synergistic proliferation in response to IL-2/15 and c-kit ligand involved both structural and functional cooperation: insights into lymphohematopoietic stem cell expansion" Philadelphia. : 4828
May 2008 Awan F, Hamadani M, Lin T, Porcu P, Blum K, Benson DM Jr, Devine SM."Comparison of allogeneic versus autologous transplantation for follicular lymphoma after transformation into diffuse large B-cell lymphoma" Alexandria.
November 2008 Blum KA, Liu Z, Lucas DM, Baiocchi R, Lin TS, Benson DM Jr , Devine SM, Jones JA, Andritsos L, Flynn J, Cheng P, Xie Z, Marcucci G, Chan KK, Grever MR, Byrd JC."Phase I evaluation of low dose decitabine targeting DNA hypermethylation in patients with CLL and NHL: dose limiting myelosuppression without evidence of hypomethylation" Washington D.C..
November 2008 Benson DM Jr , Andritsos L, Hamadani M, Lin TS, Flynn J, Jones JA, Blum W, Elder P, Lozanski G, Byrd JC, Devine SM."NK cell immune reconstitution predicts outcomes in patients with CLL undergoing allogeneic stem cell transplantation" Washington D.C..
January 2008 Schwind N and Benson DM Jr.."Malignant ascites and pericardial effusion, uncommon complications of multiple myeloma" .
January 2008 Scheier B and Benson DM Jr.."Effects of CD138 selection on sensitivity of FISH and cytogenetics on bone marrow aspirates from patients with multiple myeloma" .
January 2008 Abuzakhm S and Benson DM Jr.."An unusual case of congestive heart failure: presenting signs and symptoms of primary systemic AL amyloidosis" .
January 2008 Cohen J and Benson DM Jr."Effects of beta-blocker use on outcomes following high-dose chemotherapy and autologous stem cell support for multiple myeloma" .
December 2008 Hamadani,Mehdi; Blum,Kristie,A; Elder,Patrick; Lin,Thomas,S; Porcu,Pierluigi; Hofmeister,Craig,C; Blum,William; Marcucci,Guido; Benson,Don; Devine,Steven."Allogeneic Stem Cell Transplantation for Patients with Chemo-Refractory or Progressive Aggressive Non-Hodgkin's Lymphomas" Washington D.C.. : 0006
December 2008 Andritsos,Leslie; Hamadani,Mehdi; Heerema,Nyla,A; Benson,Don; Hofmeister,Craig,C; Blum,William; Flynn,Joseph; Jones,Jeffrey,Alan; Elder,Patrick; Lin,Thomas,S; Lozanski,Gerard; Byrd,John,C; Devine,Steven."Attainment of Minimal Residual Disease Negative State Is Crucial for Successful Outcome of Reduced Intensity Conditioning Allogeneic Stem Cell Transplantation in Advanced Chronic Lymphocytic Leukemia (CLL)" Washington D.C.. : 756
January 2009 Claybon E, Smith MK, Benson DM Jr."When a flight of stairs feels like Mount Everest: dyspnea and chest pain lead to a lymphoma diagnosis. add description" .
November 2009 Benson,Don; Bakan,Courtney,E; Zhang,Shuhong; Alghothani,Lana; Liang,Jing; Hofmeister,Craig; Srivastava,Shivani; Smith,Megan,K; Greenfield,Carli,N; Andre,Pascale; Squiban,Patrick; Romagne,Francois; Caligiuri,Michael,A; Farag,Sherif."IPH2101, a Novel Anti-Inhibitory KIR Monoclonal Antibody, and Lenalidomide Combine to Enhance the Natural Killer (NK) Cell Versus Multiple Myeloma (MM) Effect" Washington D.C..
November 2009 Benson DM Jr , Bakan CE, Zhang S, Alghothani L, Liang J, Hofmeister C, Srivastava S, Smith MK, Greenfield CN, Andre P, Squiban P, Romagne F, Caligiuri MA, Farag SS."IPH2101, a novel anti-inhibitory KIR antibody and lenalidomide combine to enhance the NK cell versus myeloma effect" Washington D.C..
January 2009 Boore S, Smith MK, Benson DM Jr."Adult epiglottitis and multiple myeloma" .
April 2009 Yu J, Wei M, Mao H, Hughes T, Trotta R, Park I, Hwang C, Liu S, Jarjoura D, Benson DM Jr , Caligiuri MA."CD94 defines a distinct NK1.1 mouse and CD56dim human natural killer cell subsets" Philadelphia.
February 2009 Hamadani M, Baiocchi R, Lin TS, Blum KA, Ezzone S, Benson DM Jr , Devine SM."Feasibility of allogeneic stem cell transplantation following RIC-conditioning in HIV positive patients with hematologic malignancies" New York.
February 2009 Hamadani M, Benson DM Jr , Porcu P, Elder P, Andritsos L, Hofmeister CC, Krugh D, Garzon R, Lin T, Marcucci G, Blum W, Devine SM."Evaluation of rabbit ATG dose intensity in patients undergoing allogeneic transplantation following reduced intensity conditioning with fludarabine, busulfan and ATG" New York.
February 2009 Grauer A, Hamadani M, Blum KA, Porcu P, Benson DM Jr , Devine SM."Allogeneic versus autologous stem cell transplantation for follicular lymphoma: The James Cancer Hospital experience" New York.
February 2009 Benson,D,M; Hofmeister,C,C; Hamadani,M; Panzner,K; Smith,M,K; Penza,S,L; Elder,P; Krugh,D; O'Donnell,L; Devine,S,M."Pre-mobilization marrow plasmacytosis predicts successful stem cell mobilization in patients with multiple myeloma receiving lenalidomide based induction regimens" New York. : 1083
January 2009 Lesinski GB, Bill MA, Fuchs JR, Li C, Bakan C, Benson DM Jr, Schwartz EB, Lin J, Hoyt DG, Fossey SL, Young GS, Warson WE III, Li PK.."Small molecule curcumin analogs induce apoptosis in human melanoma cells via STAT3 inhibition but do not alter the cellular response to immunotherapeutic cytokines." .
April 2009 Pichiorri F, Sung-Suk S, Taccioli C, Hofmeister C, Benson DM, Kuehl M, Munker R, Huebner K, Aqeilan R, Croce CM."Regulation of expression of multiple microRNAs define the cellular response to non genotoxic p53 activation in multiple myeloma cells." Philadelphia.
April 2009 Benson DM Jr , Chandler J, Mishra A, Baiocchi R, Yu J, Lin T, Lozanski G, Devine S, Porcu P, Rotem-Yehudar R, Caligiuri MA."CT-011, a PD-1 blocking antibody, enhances NK cell function against multiple myeloma" Philadelphia.
December 2009 Flinn,Ian,W; Byrd,John,C; Furman,Richard,R; Brown,Jennifer,R; Benson,Don,M; Coutre,Steven,E; Kahl,Brad,S; Smith,B,Douglas; Wagner-Johnston,Nina,D; Spurgeon,Stephen,E; Giese,Neill,A; Yu,Albert,S."Evidence of Clinical Activity in a Phase I Study of CAL-101, An Oral P110 Delta Isoform-Selective Inhibitor of Phosphatidylinositol 3-Kinase, in Patients with Relapsed or Refractory B-Cell Malignancies" Washington D.C.. : 380
December 2009 Benson DM, Romagne F, Squiban P, Wagtmann N, Farag SS, Mita A, Hofmeister CC, Smith MK, Bakan C, Caligiuri MA."Novel monoclonal antibody that enhances natural killer (NK) cell cytotoxicity against multiple myeloma (MM): Preclinical data and interim phase I clinical trial results" Alexandria.
December 2009 Benson DM Jr, Hofmeister CC, Mita A, Romagne F, Squiban P, Smith MK, Bakan C, Caligiuri MA, Farag, SS."Novel monoclonal antibody that enhances natural killer (NK) cell cytotoxicity against multiple myeloma (MM): Preclinical data and interim phase I clinical trial results" Washington D.C..
November 2010 Kahl B, Byrd JC, Flinn IW, Wagner-Johnston N, Spurgeon S, Benson DM Jr , Furman RR, Brown JR, Coutre S, Lannutti B, Giese N, Ulrich RG, Webb HK, Peterman S, Holes L, Yu AS."Clinical safety and activity in a phase I trial of CAL-101, an isoform-selective PI3K P110 delta inhibitor, in patients with relapsed or refractory NHL" Washington D.C.
November 2010 Jakubowiak,Andrzej,J; Benson,Don,M; Bensinger,William; Siegel,David,S; Zimmerman,Todd,M; Mohrbacher,Ann; Richardson,Paul,G; Afar,Daniel,EH; Singhal,Anil,K; Anderson,Kenneth,C."Elotuzumab In Combination with Bortezomib In Patients with Relapsed/Refractory Multiple Myeloma: Updated Results of a Phase 1 Study." Washington DC. : 1245
November 2010 Hofmeister,Craig,C; Bowers,Mindy,A; Lee,Seungsoo; Phelps,Mitch,A; Benson,Don,M; Kraut,Eric,H; Hicks,William,J; Deam,Deidre; Johnson,Amy,J; Farag,Sherif; Jones,Jeffrey,A; Byrd,John,C."Phase I Trial of Flavopiridol In Relapsed Myeloma: Brief Response In t(4;14) with Significant Neutropenia" Washington D.C.. : 804
December 2010 Christian,Beth; Alinari,Lapo; Earl,Christian,Tyler; Wilding,Emily; Quinion,Carl; Lustberg,Mark; Benson,Don,M; Jones,Jeffrey,A; Byrd,John,C; Wegener,William,A; Goldenberg,David,M; Baiocchi,Robert,A; Blum,Kristie,A."A Phase I Study of Milatuzumab, a Humanized Anti-CD74 Antibody, and Veltuzumab, a Humanized Anti-CD20 Antibody, In Patients with Relapsed and Refractory B-Cell Non-Hodgkin's Lymphoma" Washington D.C..
February 2010 Hamadani M, Craig M, Abraham J, Tse W, Cumpston A, Stotler CJ, Remick P, Bunner S, Leadmon P, Elder P, Hofmeister C, Penza S, Andritsos L, Blum W, Benson DM Jr , Devine SM."Evaluation of busulfan dose intensity in patients undergoing allogeneic transplantation with two different fludarabine/busulfan/ATG based reduced intensity conditioning regimens" New York.
December 2010 Jones,Jeffrey,A; Andritsos,Leslie; Baiocchi,Robert; Benson,Don,M; Blum,Kristie,A; Christian,Beth; Deam,Deidre; Flynn,Joseph,M; Johnson,Amy,J; Phelps,Mitch,A; Porcu,Pierluigi; Byrd,John,C; Grever,Michael,R."Flavopiridol Can Be Safely Administered Using a Pharmacologically Derived Schedule and Demonstrates Activity In Relapsed and Refractory Non-Hodgkin's Lymphoma" Washington D.C.. : 1169
December 2010 Hofmeister,Craig,C; Rieser,Gisele; Bowers,Mindy,A; Merritt,Lisa,C; Greenfield,Carli,N; Efebera,Yvonne,A; Benson,Don,M; Devine,Steven,M; De Moor,Janet,S."Tablet-Based Assessment of Fatigue, Depression, and Pain In Myeloma Patients: Cohort Study of Inflammatory Cytokines and QOL Measures In the Newly Diagnosed, Patients on Lenalidomide, and Survivors." Washington D.C..
December 2010 Habib,Joyce; Dunavin,Neil; Phillips,Gary; Elder,Patrick; Tranovich,Meaghan; Benson,Don,M; Hofmeister,Craig,C; Byrd,John,C; Devine,Steven,M; Efebera,Yvonne."Analysis of 179 Patients with Newly Diagnosed Multiple Myeloma (MM) Treated with Novel Agents Followed by Autologous Stem Cell Transplantation (ASCT): a Retrospective Study" Washington D.C.. : 575
December 2010 Dunavin,Neil; Habib,Joyce; Phillips,Gary; Elder,Patrick; Tranovich,Meaghan; Benson,Don,M; Hofmeister,Craig,C; Byrd,John,C; Devine,Steven,M; Efebera,Yvonne."Early Versus Delayed Autologous Stem Cell Transplant In Patients Receiving Novel Therapies for Multiple Myeloma" Washington D.C..
September 2010 Mori S, Crawford B, Roddy J, Phillips G, Elder P, Hofmeister C, Efebera Y, Greenfield C, Rose K, Benson DM Jr."Serum free light chains add to M-protein in response assessment of newly diagnosed patients with myeloma receiving novel therapies and may hold unique, a priori prognostic power prior to HDC/SCT" Bath, UK.
November 2010 Furman R, Byrd JC, Brown JR, Coutre S, Benson DM Jr , Wagner-Johnston N, Flinn IW, Kahl B, Spurgeon SE, Lannutti B, Giese N, Webb HK, Ulrich RG, Peterman S, Holes L, Yu AS."CAL-101, an isoform-selective inhibitor of PI3K P110 delta, demonstrates clinical activity and PD effects in patients with relapsed/refractory CLL" Washington D.C..
June 2010 Benson DM, Padmanabahn S, Hofmeister CC, Bakan C, Abonour R, Suvannasankha A, Efebera Y, Squiban P, Caligiuri MA, Farag SS."A phase 1 trial of IPH2101, a novel anti-inhibitory KIR monoclonal antibody, in patients with multiple myeloma." Alexandria.
January 2011 Jonathon B. Cohen, Nathan Hall, Amy S. Ruppert, Jeffrey A. Jones, Pierluigi Porcu, Robert A. Baiocchi, Sam Penza, Don M Benson, Jr., Leslie A Andritsos, Joseph M. Flynn, Steven M. Devine, and Kristie A Blum."The Prognostic Value of FDG PET/CT Prior to Autologous Stem Cell Transplant in Mantle Cell Lymphoma" . : 3113
May 2011 Benson DM, Bakan C, Hofmeister C, Efebera Y, Suvannasankha A, Jagannath S, Abonour R, Chari A, Padmanaban S, Romagne F, Andre P, Blanchet S, Buffet R, Caligiuri MA, Farag SS."Phase I trial of IPH-2101, a novel anti-inhibitory KIR antibody, in patients with multiple myeloma" Italy.
January 2011 Don M. Benson, Jr, Courtney E. Bakan, Shuhong Zhang, Shauna M. Collins, Jing Liang, Shivani Srivastava, Craig C. Hofmeister, Yvonne Efebera, Pascale Andre, Francois Romagne, Mathieu Bléry, Cécile Bonnafous, Jianying Zhang, David Clever, Michael A. Caligiuri, and Sherif S. Farag."IPH2101, a novel anti-inhibitory KIR antibody, and lenalidomide combine to enhance the natural killer cell versus multiple myeloma effect" . : 6387
February 2011 Collins S, Bakan CE, Hofmeister CC, Efebera Y, Benson DM Jr."Interim results of a phase I trial of IPH-2101, a novel anti-inhibitory KIR antibody, in patients with multiple myeloma" Seven Springs.
February 2011 Bakan CE, Collins SM, Benson DM Jr."Lenalidomide and IPH2101, a novel anti-inhibitory KIR antibody, combine to enhance NK cell cytotoxicity against multiple myeloma" Seven Springs.
December 2011 Cohen JB, Hall N, Ruppert AS, Jones JA, Porc P, Baiocchi RA, Penza S, Benson DM, Andritsos LA, Flynn J, Devine SM, Blum KA."The Prognostic Value of FDG PET/CT Prior to Autologous Stem Cell Transplant in Mantle Cell Lymphoma." Washington D.C..
January 2011 Beth Christian, Lapo Alinari, Jeffrey A. Jones, Don M Benson, Jr., Joseph M. Flynn, Pierluigi Porcu, Mark E Lustberg, Mitchell Phelps, Ming Poi, Diana Chung, Carl Quinion, John C. Byrd, William Wegener, David M Goldenberg, Robert A. Baiocchi, and Kristie A. Blum."Results of A Phase I Study of Milatuzumab, a Humanized Anti-CD74 Antibody, and Veltuzumab, a Humanized Anti-CD20 Antibody, In Patients with Relapsed and Refractory B-Cell Non-Hodgkin's Lymphoma," . : 3707
April 2011 Collins SM, Bakan CE, Benson DM Jr."Elotuzumab stimulates NK cell function against multiple myeloma" .
June 2011 Jakubowiak A, Benson DM, Bensinger W, Siegel D, Zimmerman T, Mohrbacher A, Richardson P, Afar D, Singhal A, Anderson KC."Dose escalation phase I trial of elotuzumab given with fixed-dose bortezomib in patients with relapsed or refractory multiple myeloma." Alexandria.
June 2011 Collins SM, Bakan CE, Alghothani Y, Kwon H, Balasa B, Starling G, Rice A, Benson DM."The effect of elotuzumab on natural killer cell function against multiple myeloma." Alexandria.
September 2011 Coutre SE, Byrd JC, Furman RR, Brown JR, Benson DM, Wagner-Johnston ND, Flinn IW, Kahl BS, Spurgeon SEF, Lannutti BJ, Hsu HKW, Ulrich R, Peterman S, Holes L, Miller LL, Yu AS.."Phase I study of CAL-101, an isoform-selective inhibitory of phosphatidylinositol e-kinase P110d, in patients with previously treated chronic lymphocytic leukemia." Alexandria.
April 2011 Collins SM, Benson DM Jr."Results of a phase I trial in multiple myeloma with IPH-2101" Columbus.
Ali, Y & Benson, DM Jr."Blood is thicker than water: a case of Waldemstrom’s macroglobulinemia and review" .

Presentations

"Characteristics of chunking non-adjacent items in rat serial pattern learning." Washington, DC. (November 1993)

"Chunking interleaved patterns in rat serial pattern learning." Chicago, IL. (May 1994)

"The effects of dl-amphetamine on environmental expectations in ratsThe effects of fdl-amphetamine on environmental expectations in rats." Chicago, IL. (May 1994)

"Pattern structure influences learning and memory in rat serial pattern learning." Presented at Annual Research Colloquium, . (January 1995)

"Interleaved Serial Pattern Learning." Presented at Tri-State Conference on Comparative Cognition, Columbus, OH. (April 1995)

"Subpattern structure determines acquisition of interleaved serial patterns." Presented at Annual Meeting, Chicago, IL. (May 1995)

"Determining the physiological and cognitive mechanisms underlying rat serial pattern learning." Chicago, IL. (May 1997)

"Diagnosing malignancy using closed bone biopsy at small community hospital." Akron, OH. (September 1997)

"State of the Art: Treatment of intracranial metastatic malignancy.." MD. (January 1998)

"Pattern structure influences learning and memory in rat serial pattern learning." . (January 1998)

"Tracking shifted subpatterns: New evidence for rule sensitivity in rat interleaved serial pattern learning." Presented at Annual Meeting, Chicago, IL. (January 1999)

"Comparing predictive values of theories explaining rat serial performance." Presented at Annual Meeting, Chicago, IL. (January 1999)

"Humility and Courage." OH. (January 1999)

"CRH-induced metabolic disarray associated with prostate cancer paraneoplastic syndrome." . (April 2001)

"Blood is thicker than water: a case of Waldemstrom’s macroglobulinemia and review." . (January 2003)

"Molecular determinants of proliferative synergy between interleukin-2 and the c-kit ligand in human natural killer cells." Presented at 6th Annual post-graduate research day, Columbus, OH. (January 2003)

"A dynamic strategy for reducing internal medicine work hours." . (January 2003)

"Spirituality and Religion at the End of Life." VA. (January 2003)

"Re-slicing the American Health Care Pie, when we really need loaves and fishes: American health care delivery integrated with Catholic medical ethics.." Wheeling, WV. (January 2003)

"Molecular mechanisms of cytokine directed natural killer cell based therapyproliferation: from basic science to clinical applications." Presented at Grand Rounds, Division of Hematology/Oncology, . (January 2006)

"Non-hodgkin lymphoma for the family practitioner.." Presented at Recognizing Blood Cancers in the Family Practice, Columbus, OH. (October 2006)

"10 things you need to know about Multiple Myeloma." Columbus, OH. (September 2007)

"Natural Killer cells and amyloidosis: mechanism and translation." Detroit, MI. (October 2007)

"Natural Killer cells and amyloidosis: therapeutic potential and promise.." Presented at Amyloidosis Support Network meeting, Detroit, MI. (October 2007)

"“Why should patients with cancer participate in clinical trials?�." Presented at Grand Rounds, Department of Internal Medicine, Columbus, OH. (August 2007)

"NK cell therapy for cancer." Copenhagen, DK|DNK. (January 2007)

"Hematology Board Review." Columbus, OH. (January 2007)

"Multiple Myeloma, new updates." Columbus, OH. (March 2007)

"Multiply Myeloma: translating discoveries into emerging therapies." Presented at Hemtology & Oncology Grand Rounds, Wheeling, WV. (December 2007)

"Amyloidosis update." Columbus, OH. (March 2008)

"Multiple Myeloma: translating new evidence into clinical practice.." Kettering, OH. (May 2008)

"Hematology Board Review." Columbus, OH. (May 2008)

"Restoring and augmenting natural killer cell immunity in patients with B-Cell malignancies." Lake Orta, IT|ITA. (June 2008)

"Promising research in multiple myeloma." Columbus, OH. (June 2008)

"The role of natural killer cells in hematopoietic stem cell and solid organ transplantation." Presented at Comprehensive Transplant Center Grand Rounds, Columbus, OH. (January 2008)

"The promise of natural killer cells in cancer therapy: from bench to bedside.." Presented at Department of Stem Cell Transplantation Grand Rounds, Houston, TX. (January 2008)

"Promising research in multiple myeloma." Presented at Lecture for patients and families at Leukemia and Lymphoma Society patient / family meeting, Columbus, OH. (January 2008)

"Natural Killer Cell Immunity in Chronic Lymphocytic Leukemia." Houston, TX. (January 2008)

"Multiple Myeloma review." Columbus, OH. (January 2008)

"Emerging front line therapies for multiple myeloma." Charlotte, NC. (August 2009)

"What is Amyloidosis?." Presented at Multidisciplinary Seminar Series: James Cancer Hospital and Solove Research Institute, Columbus, OH. (September 2009)

"Seminar series: Diagnosis and Management of Multiple Myeloma." Columbus, OH. (January 2009)

"Hematology Board Review." Columbus, OH. (January 2009)

"Augmenting natural killer cell function: towards a novel therapeutic strategy in patients with multiple myeloma." Presented at Department of Pathology Grand Rounds, Columbus, OH. (January 2009)

""Hope" from a physician-scientist’s perspective: advances in the research and treatment of multiple myeloma." Columbus, OH. (February 2010)

"Augmenting natural killer cell function for myeloma therapy." Presented at Translational Research Cancer Centers Consortium Conference, Columbus, OH. (March 2010)

"Update in Blood Cancer Research." Presented at Leukemia and Lymphoma Society Light the Night Campaign, Columbus, OH. (September 2010)

"On suffering: a Catholic perspective." Columbus, OH. (September 2010)

"Natural killer cell cytotoxicity is enhanced via therapeutic targeting of the PD-1/PD-L1 signaling axis.." Tel Aviv, IL|ISR. (November 2010)

"Update on induction regimens for multiple myeloma." Columbus, OH. (January 2010)

"Towards a Phase II trial of CT-011, an anti-PD-1 antibody, and lenalidomide for patients with multiple myeloma: translation of preclinical evidence and study design." Presented at Teva Research Colloquium, Tel Aviv, IL|ISR. (January 2010)

"Cases in abnormal hematology." Presented at Annual Ohio Collaborative Clinical Laboratories Meeting, Strongsville, OH. (January 2010)

"Pelotonia funding for cancer research at The James." Bexley, OH. (August 2010)

"What is an immunoglobulin?." Columbus, OH. (September 2011)

"Cancer Research at The James." Presented at Lunch and Learn Series, Columbus, OH. (April 2011)

"The promise of current research in blood cancers." Columbus, OH. (May 2011)

"The future of treatment for multiple myeloma." Columbus, OH. (May 2011)

"Updates in Hematology from the 2011 ASCO meeting." Presented at American Society of Clinical Oncology Annual Meeting Review, Columbus, OH. (June 2011)

"“End-of-life issues from a Catholic perspective�." Columbus, OH. (January 2011)

 

Professional Activities

2007 - present Team in Training / Columbus Marathon. Leukemia and Lymphoma Society. Columbus, OH.
2007 - present Leukemia and Lymphoma Society. Team in Training. Columbus, OH.
2007 - present MMORE. Multiple Myeloma Opportunities for Research and Education. Columbus, OH.
2008 - present Amyloidosis Support Network. Amyloidosis Support Network.
2008 - present Leukemia and Lymphoma Society. Leukemia and Lymphoma Society.
2008 - present Consultant. CureTech, LTD.
2008 - present Consultant. Innate Pharma, Inc..
2008 - present Consultant. new Mentor.
2009 - present Consultant. North American Center for Continuing Medical Education.
2009 - present Consultant. Bristol Myers - Squibb.
2009 - present Consultant. Facet Biotechnology.
2009 - present Consultant. Abbott Laboratories.
2009 - present Pelotonia. Pelotonia. Columbus, OH.
2009 - present Rider, Speaker, & Volunteer. Pelotonia. Columbus, OH.
2010 - present Scientific Advisory Board. Multiple Myeloma Opportunities for Research and Educaiton (MMORE). Columbus, OH.
2011 - present Columbus Marathon. Team in Training. Columbus, OH.
2012 - present Pelotonia rider recruitment speaker. Pelotonia. Columbus, OH.
2006 - 2009 Consultant. Novo Nordisk, Inc..
2007 - 2010 Wheeling Jesuit University - Member of Board of Directors. Wheeling Jesuit University.
2011 Host and Presenter. Pelotonia Laboratory Tours. Columbus, OH.
 

Technical Reports

Benson DM Jr. “Special Report on ASCO 2006: Anemia, Neutropenia, and Mucositis. A continuing education newsletter for physicians, nurses and pharmacists.”. West Conshohocken, PA, US|USA: Meniscus Education and Communication. (January 2006).

 

Unpublished Works

Jaglowski S, Stark A, Hofmeister CC, Elder P, Blum W, Klisovic R, Vasu S, Penza S, Efebera Y, Benson DM Jr, Devine SM, Andritsos LA. The hematopoietic stem cell transplant comorbidity index can predict for 30-day readmission following autologous stem cell transplant for lymphoma and myeloma. April 2014.

Hofmeister CC, Williams N, Geyer S, Bingman A, Bowers MA, Humphries K, Lozanski G, Baiocchi RA, Flynn J, Penza s, Benson DM Jr, Hade EM, Andritsos LA, Devine SM. A phase 1 study of vorinostat maintenance after autologous stem cell transplant in high risk lymphoma. April 2014.

Kohrt H, et al., Benson DM Jr. Guidelines for monitoring immunodynamics in clinical trials.

Salem G, Ruppert AS, Elder P, Hofmeister CC, Benson DM Jr, Penza S, Andritsos LA, Klisovic R, Vasu S, Blum W, Devine SM, Jalowski S, Efebera YA. Lower dose of antithymocyte globulin (ATG) decreases infection rate without increasing graft-versus-host disease (GVHD) and relapse in patients undergoing reduced intensity conditioning (RIC) allogeneic hematopoietic stem cell transplant (allo HSCT). December 2013.

Bhaskar S & Benson DM Jr. Current and future immunotherapeutic approaches to multiple myeloma therapy. April 2014.

Sborov DW, Nuovo GJ, Stiff A, Mace T, Lesinski G, Benson DM Jr, Efebera YA, Rosko AE, Pichiorri F, grever MR< Hofmeister CC. A phase 1 trial of reolysin alone in patients with relapsed multiple myeloma.

Roddy JVF, Haverkos BM, McBride A, Leininger KM, Jalowski S, Penza S, Klisovic R, Blum W, Vasu S, Hofmeister CC, Benson DM Jr, Andritsos LA, Devine SM, Efebera YA. Tocilizumab for steroid refractory acute graft versus host disease.

Chu B, Sell M, Tucker j, Shana'ah A, Hofmeister CC, Pichiorri F, Benson DM Jr, Efebera YA. Long term therapy with lenalidomide in a patient with POEMS syndrome. December 2013.

Hughes TL, Yu J, McClory S, Briercheck E, Cole J, Harrison N, Mao C, Benson DM Jr, Efebera YA. Antagonism of aryl hydrocarbon receptor promotes the functional maturation of immature human natural killer clls in secondary lymphoid tissue. March 2014.